H2 tag- SEO Purpose
CV: Cardiovascular; DDD: Defined daily dose; DAPT: Dual anti-platelet therapy; GI: Gastrointestinal; GIB: GI bleeding; OR: Odds ratio; PPI: Proton pump inhibitor; UGIB: Upper gastrointestinal bleeding, VONOPrazan; No drug-drug interaction; sustained relief; Supported by Meal independent dosing
Low-dose aspirin reduces CV events by ~25% than non-use but increases GI events by 2–5 folds.1
Clopidogrel prevents CV events but is linked to adverse GI complications, including GIB.2
A nationwide population-based cohort study investigated clopidogrel for the risk of adverse GI events including gastritis, GI ulcers, or bleeding.2
Highest observed OR=1.91 indicated clopidogrel usage being ~91% more likely to cause adverse GI events.2
As shown in the figure, VONOprazan can help mitigate this risk, reducing upper GI bleeding in dual antiplatelet therapy by 1.4x compared to PPIs.3
Vono-Always on Duty
Vono, containing Vonoprazan molecule, is a Potassium Competitive Acid Blocker which helps in treatment of Refractory GERD, Erosive Esophagitis, H.Pylori, Gastric & Duodenal Ulcers
